




**STATE MEDICAID P&T COMMITTEE MEETING**  
**THURSDAY, May 16, 2013**  
**7:00 a.m. to 8:30 a.m.**  
**Cannon Health Building**  
**Room 128**



## MINUTES

**Committee Members Present:**

Ellie Brownstein, M.D.  
 Lisa Hunt, R.Ph.  
 Bernadette Kiraly, M.D.  
 Julia Ozbolt, M.D.  
 Elizabeth Young, Pharm.D.

Kort Delost, R.Ph.  
 Beth Johnson, R.Ph.  
 Roger Martenau, M.D.  
 Jameson Rice, Pharm.D.

**Committee Members Excused:**

none

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Richard Sorenson, R.N. Trevor Smith, CPhT

**University of Utah Drug Information Center Staff Present:**

Melissa Archer, Pharm.D. Gary Oderda, PharmD

**Other Individuals Present:**

|                                  |                                     |
|----------------------------------|-------------------------------------|
| Linda Craig, AstraZeneca         | Paul Bonham, Novo Nordisk           |
| Dale Crawford, Novo Nordisk      | Mike Ketcher, Novo Nordisk          |
| Scott Larson, BMS                | Robert Garr MD, Tooele County       |
| Adam Johnson, BMS                | Raphael Wilson, BMS                 |
| Efrain Alton, Merck              | Eric Anderson, AstraZeneca          |
| Toby Zirkle, Diabetes Specialist | Lisa Sterbenz, Novo Nordisk         |
| Derek Butters, Novo Nordisk      | Nancy Futrell, Intermountain Stroke |
| Alan Bailey, Pfizer              | Steve Warren                        |
| Wayne Roberts, GSK               |                                     |

Meeting conducted by: Ellie Brownstein

---

1. Review and Approval of April Minutes: Beth Johnson moved to approve the minutes, Jameson Rice seconded the motion. Motion approved unanimously.
2. Housekeeping: Lisa Hunt reported that seven new classes to be added to the PDL. Sedative Hypnotics, H2 Agonists, and Antivirals are to be added. Grandfathering of drugs will be used to prevent disruption of care with the coming changes.
3. Drug Utilization Review (DUR) Board update: Robyn Seely was not present for the

meeting. Her update will take place in the next meeting.

4. Melissa Archer provided instruction on Factor XA inhibitors. For many years warfarin has been the only oral anticoagulant therapy. There are new developments in oral agents that are new to the market including Pradaxa (dabigatran), Eloquis (Apixaban), Xarelto (Rivaroxaban), and Arixtra (Fondaparinux). Melissa will describe only Eloquis, Arixtra, and Xarelto today for potential inclusion on the PDL. Instruction related to safety and efficacy, usage for each product based on disease state, studies and trials, and historical claim data for each drug was presented. No direct comparative evidence is present in relation for the presented Xa inhibitors. Compared to other agents, factor Xa inhibitors demonstrate safety and efficacy in the treatment or prevention of thrombosis. Recommended usage should be based on labeled indications, guideline recommendation and patient specific characteristics.
5. Lisa presented on the Other States Report of the Xa inhibitor. Utilization data for the Xa inhibitors was also presented.
6. Public Comment
  - a. Lori Blackner PharmD. (Pfizer, Eloquis) – Eloquis data presented including safety and efficacy, dosing information, warnings, studies and trials, and other information was presented.
  - b. Nancy Futrell MD (Intermountain Stroke Center) – discussed the practical issues of managing patients with stroke on blood thinners. Described warfarin as a dirty drug with many undesirable side effects. The quick action of new Xa drugs is very beneficial. Expressed the need of patients to wear identification about their medication history in the event of an emergency event.
  - c. Laura Litzenberger PharmD – (Janseen, Xarelto) - Xarelto data presented including safety and efficacy, dosing information, warnings, studies and trials, and other information was presented.
  - d. Robert Garr DO – (Cardiologist) – Compared the Xa's to Lovenox in pill form. Said that the speed that new drugs work is very helpful in comparison to warfarin.
7. Discussion of Xa inhibitors by the board
  - a. Beth Johnson said that Xa have many advantages but biggest drawback is if in an emergency situation or under care of different physician, there is a chance of mis treatment with other coagulation therapy drugs.
  - b. Bernadette Kiraly asked what can be done, use of database, or education article.
  - c. Lisa Hunt told the board about the Amber Sheet and asked for help in preparing an education article for providers about this issue. Beth Johnson, Elizabeth Young, Jameson Rice and others said they would help out with the preparation of this material.
  - d. Kort Delost asked if there were concerns about indications.
  - e. Jameson Rice said that it would be best to not limit the agents as there is no big difference in safety and efficacy.
  - f. Beth Johnson said it would be beneficial to revisit this class in the future after

- new evidence is presented.
- g. Jameson Rice makes a motion to include all the agents into the PDL to help ensure quality care in rural areas where transportation to Coumadin Clinics is difficult at times.
  - h. Lisa Hunt asked for clarification if he means to include means make the all preferred.
  - i. Jameson Rice says that he means to make them all preferred.
  - j. Motion by Jameson Rice is seconded by Roger Martenau. Motion carries.
8. Melissa Archer presents education on GLP-1 receptor agonists. Three of these agents are available on the market currently. They include Byetta, Bydureon (exenatide) and Victoza (liraglutide). GLP-1 are not to be used as a first line therapy for type 2 diabetes. All GLP-1 medications reported on were efficacious in reducing A1c levels in patients with type 2 diabetes. Instruction related to safety and efficacy, usage for each product based on disease state, studies and trials, and historical claim data for each drug was presented. Choice of agent should be based on individual patient specific characteristics, cost, potential adverse effects, and patient preference.
9. Lisa presented data from others states preference in coverage.
10. Public comment
- a. Adam Johnson, PharmD (BMS, Byetta & Bydureon) - Byetta and Bydureon data presented including safety and efficacy, dosing information, warnings, studies and trials, and other information was presented.
  - b. Mike Ketcher, PharmD (Novo Nordisk, Victoza) – Victoza data presented including safety and efficacy, dosing information, warnings, studies and trials, and other information was presented.
11. Discussion of GLP-1 agents by the board
- a. Bernadette Kiraly mentioned the potential differences between the medications and how they will relate to patient compliance; The different medications are taken once daily vs twice daily vs once weekly. Fewer injections necessary are more attractive.
  - b. Kort Delost and Jameson Rice reported that they have not seen usage in their pharmacies of these medications.
  - c. Lisa Hunt restated that the goal of the committee is to determine if the drugs are equally safe or effective.
  - d. Bernadette Kiraly said that there is a slight superiority for Victoza over the other agents in reducing A1c.
  - e. Kort Delost said that in looking at other states data, there is many that have these drugs listed as preferred agents.
  - f. Bernadette Kiraly makes a motion to make all GLP-1 are equally safe and effective. Lisa Hunt seconds this motion. All approve on the motion.
  - g. Kort asked that with this motion of the agents being equally safe and effective, should the state decide which agents to make preferred.
  - h. Bernadette Kiraly made a motion by saying “considering the trending toward

improved mean A1c reduction and ease of dosing, I would move that Vicotza be included specifically.” Jameson Rice seconded the motion. Lisa Hunt and Kort Delost were opposed to the motion. All other board members were for the motion. Motion carried.

12. Lisa provided members of the board with a copy of the Robert’s Rules of Order to review.

13. Meeting adjourned.

Next Meeting Set for Thursday, July 18, 2013 - Sulfonylurea drug class

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)